Thromboelastography to Study Burn Coagulopathy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFrancesco Egro
About this trial
This pilot study examines the use of thromboelastography (TEG), a specialized blood test, to evaluate clotting abnormalities in burn patients. The study aims to understand how burn injuries impact the body's ability to form and break down blood clots over time. Specifically, the investigators will research whether the percentage of total body surface area burned (%TBSA) is associated with changes in blood clotting, track the evolution of clotting patterns during the first four weeks following a burn injury, and explore whether these changes can predict recovery or complications. By providing new insights into clotting dynamics in burn patients, the study seeks to improve diagnostic methods, enhance monitoring strategies, and guide treatments to optimize patient care and outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients admitted with acute burn injuries
Aged 18 years and older
Provided consent to participate in the study
Disqualifiers
Patients with a history of venous thromboembolism or hyper/hypocoagulopathy
Trial design
Design model
Single group
Treatments tested in this trial
Thromboelastography
Diagnostic testAll participants will receive this intervention. Thromboelastography (TEG) is a blood test that provides a detailed assessment of the clotting process, measuring how blood clots form, strengthen, and dissolve. It offers real-time insights into a patient's coagulation status, helping to identify clotting disorders and guide treatment decisions.
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: Burn Thromboelastography GroupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Thromboelastography
Thromboelastography (TEG) evaluates blood's clotting ability by measuring the strength and elasticity of a clot over time, producing a dynamic graph. The following outcome measures will be assessed at specific time points (Day 1, Day 7, Day 14, Day 21, and Day 28): 1. Reaction Time (R) (seconds) - The time from test initiation until the first detectable clot formation. 2. Kinetic Time (K) (seconds) - The time from initial clot formation to a defined clot strength threshold. 3. Maximum Amplitude (MA) (millimeters) - The peak strength of the formed clot. 4. Alpha Angle (degrees) - The slope of the clot formation curve, representing the rate of clot development. 5. Lysis at 30 Minutes (Ly30) (percentage of MA) - The percentage of clot degradation occurring 30 minutes after reaching maximum amplitude. Each parameter will be measured at the specified time points, and values will be aggregated into one TEG graph.
Time frame
Duration of hospital length of stay, up to 28 daysSecondary outcomes
1
Hospital Length of Stay
The investigators will measure the number of days patients stay in the hospital for treatment.
Time frame
Duration of hospital length of stay, up to 28 days2
Complications During Treatment
The investigators will record any complications, such as infections, graft loss, flap loss, or thrombosis that occur during treatment.
Time frame
Duration of hospital length of stay, up to 28 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Francesco Egro
Lead sponsor
University of Pittsburgh
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: